306 related articles for article (PubMed ID: 31752049)
1. Non-alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor.
Sawada K; Hayashi H; Nakajima S; Hasebe T; Fujiya M; Okumura T
J Gastroenterol Hepatol; 2020 Jun; 35(6):1042-1048. PubMed ID: 31752049
[TBL] [Abstract][Full Text] [Related]
2. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.
Matsuoka H; Hayashi T; Takigami K; Imaizumi K; Shiroki R; Ohmiya N; Sugiura K; Kawada K; Sawaki A; Maeda K; Ando Y; Uyama I
BMC Cancer; 2020 Jul; 20(1):656. PubMed ID: 32664888
[TBL] [Abstract][Full Text] [Related]
3. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
4. Characterization and Prognostic Significance of Cutaneous Adverse Events to Anti-Programmed Cell Death-1 Therapy.
Lee YJ; Kim HT; Won CH; Chang SE; Lee MW; Choi JH; Lee WJ
J Korean Med Sci; 2019 Jul; 34(26):e186. PubMed ID: 31269545
[TBL] [Abstract][Full Text] [Related]
5. Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review.
Onoyama T; Takeda Y; Yamashita T; Hamamoto W; Sakamoto Y; Koda H; Kawata S; Matsumoto K; Isomoto H
World J Gastroenterol; 2020 Jan; 26(3):353-365. PubMed ID: 31988594
[TBL] [Abstract][Full Text] [Related]
6. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.
Nakanishi Y; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Tsutani Y; Iwamoto H; Fujitaka K; Miyata Y; Hamada H; Okada M; Hattori N
Respir Investig; 2019 Sep; 57(5):451-459. PubMed ID: 31248832
[TBL] [Abstract][Full Text] [Related]
7. Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience.
Vitale G; Lamberti G; Comito F; Di Nunno V; Massari F; Morelli MC; Ardizzoni A; Gelsomino F
Expert Opin Biol Ther; 2020 Sep; 20(9):1047-1059. PubMed ID: 32425081
[TBL] [Abstract][Full Text] [Related]
8. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
Rogado J; Sánchez-Torres JM; Romero-Laorden N; Ballesteros AI; Pacheco-Barcia V; Ramos-Leví A; Arranz R; Lorenzo A; Gullón P; Donnay O; Adrados M; Costas P; Aspa J; Alfranca A; Mondéjar R; Colomer R
Eur J Cancer; 2019 Mar; 109():21-27. PubMed ID: 30682533
[TBL] [Abstract][Full Text] [Related]
9. Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
Kitagataya T; Suda G; Nagashima K; Katsurada T; Yamamoto K; Kimura M; Maehara O; Yamada R; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Umemura M; Kawagishi N; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Ohnishi S; Komatsu Y; Hata H; Takeuchi S; Abe T; Sakakibara-Konishi J; Teshima T; Homma A; Sakamoto N
J Gastroenterol Hepatol; 2020 Oct; 35(10):1782-1788. PubMed ID: 32187734
[TBL] [Abstract][Full Text] [Related]
10. Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy.
Shafqat H; Gourdin T; Sion A
Semin Oncol; 2018 Jun; 45(3):156-163. PubMed ID: 30348532
[TBL] [Abstract][Full Text] [Related]
11. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.
Belkhir R; Burel SL; Dunogeant L; Marabelle A; Hollebecque A; Besse B; Leary A; Voisin AL; Pontoizeau C; Coutte L; Pertuiset E; Mouterde G; Fain O; Lambotte O; Mariette X
Ann Rheum Dis; 2017 Oct; 76(10):1747-1750. PubMed ID: 28600350
[TBL] [Abstract][Full Text] [Related]
12. A detection algorithm for drug-induced liver injury in medical information databases using the Japanese diagnostic scale and its comparison with the Council for International Organizations of Medical Sciences/the Roussel Uclaf Causality Assessment Method scale.
Hanatani T; Sai K; Tohkin M; Segawa K; Kimura M; Hori K; Kawakami J; Saito Y
Pharmacoepidemiol Drug Saf; 2014 Sep; 23(9):984-8. PubMed ID: 24596340
[TBL] [Abstract][Full Text] [Related]
13. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Weber JS; Postow M; Lao CD; Schadendorf D
Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
[TBL] [Abstract][Full Text] [Related]
14. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.
Hofmann L; Forschner A; Loquai C; Goldinger SM; Zimmer L; Ugurel S; Schmidgen MI; Gutzmer R; Utikal JS; Göppner D; Hassel JC; Meier F; Tietze JK; Thomas I; Weishaupt C; Leverkus M; Wahl R; Dietrich U; Garbe C; Kirchberger MC; Eigentler T; Berking C; Gesierich A; Krackhardt AM; Schadendorf D; Schuler G; Dummer R; Heinzerling LM
Eur J Cancer; 2016 Jun; 60():190-209. PubMed ID: 27085692
[TBL] [Abstract][Full Text] [Related]
16. Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy.
Liew DFL; Leung JLY; Liu B; Cebon J; Frauman AG; Buchanan RRC
Int J Rheum Dis; 2019 Feb; 22(2):297-302. PubMed ID: 30549256
[TBL] [Abstract][Full Text] [Related]
17. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
Miyahara K; Noda T; Ito Y; Hidaka H; Fujimoto S; Takedomi H; Akutagawa T; Sakata Y; Shimamura T; Tominaga N; Yamaguchi D; Fujimoto K
Digestion; 2020; 101(1):60-65. PubMed ID: 31801131
[TBL] [Abstract][Full Text] [Related]
18. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
19. Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies.
Kao JC; Liao B; Markovic SN; Klein CJ; Naddaf E; Staff NP; Liewluck T; Hammack JE; Sandroni P; Finnes H; Mauermann ML
JAMA Neurol; 2017 Oct; 74(10):1216-1222. PubMed ID: 28873125
[TBL] [Abstract][Full Text] [Related]
20. New and Worsening Long-term Immune-Related Adverse Events with PD-1/PD-L1 Pathway Agents in Patients with Cancer.
Hall KH; Liu Y; Jiang C; Harvey RD
Pharmacotherapy; 2020 Feb; 40(2):133-141. PubMed ID: 31863604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
